| 6.11 -0.87 (-12.46%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.09 |
1-year : | 9.37 |
| Resists | First : | 6.93 |
Second : | 8.02 |
| Pivot price | 7.11 |
|||
| Supports | First : | 5.15 |
Second : | 4.29 |
| MAs | MA(5) : | 6.89 |
MA(20) : | 7.02  |
| MA(100) : | 4.22 |
MA(250) : | 2.64 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 23.4 |
D(3) : | 36.5 |
| RSI | RSI(14): 41.6 |
|||
| 52-week | High : | 8.02 | Low : | 1.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CLYM ] has closed below the lower bollinger band by 35.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CLYM ] is to continue within current trading range. Bollinger Bands are 28.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.11 - 7.16 | 7.16 - 7.19 |
| Low: | 5.91 - 5.96 | 5.96 - 5.99 |
| Close: | 6.05 - 6.12 | 6.12 - 6.17 |
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Fri, 20 Mar 2026
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Wed, 18 Mar 2026
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? - MSN
Wed, 18 Mar 2026
Climb Bio (CLYM) Receives 'Buy' Rating from Truist Securities | - GuruFocus
Tue, 17 Mar 2026
Truist initiates Climb Bio stock with buy rating on drug potential - Investing.com
Thu, 12 Mar 2026
Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026 - Meyka
Thu, 05 Mar 2026
Autoimmune drug trials at Climb Bio target 2026 data wave - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 53.3 (%) |
| Shares Short | 1,920 (K) |
| Shares Short P.Month | 1,800 (K) |
| EPS | -0.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.1 % |
| Return on Equity (ttm) | -32.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -10.36 |
| PEG Ratio | 0 |
| Price to Book value | 1.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|